Alnylam Pharmaceuticals, Inc.
ALNY
$251.56
$8.953.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 18.42% | -24.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.42% | -24.08% | |||
| Cost of Revenue | 19.69% | 25.09% | |||
| Gross Profit | 18.15% | -29.80% | |||
| SG&A Expenses | 33.64% | -11.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.85% | -5.46% | |||
| Operating Income | -36.74% | -258.20% | |||
| Income Before Tax | -78.49% | -873.07% | |||
| Income Tax Expenses | -3,890.68% | -49.20% | |||
| Earnings from Continuing Operations | 24.92% | -560.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 24.92% | -560.61% | |||
| EBIT | -36.74% | -258.20% | |||
| EBITDA | -44.61% | -198.91% | |||
| EPS Basic | 25.23% | -550.86% | |||
| Normalized Basic EPS | -80.23% | -977.64% | |||
| EPS Diluted | 25.44% | -552.66% | |||
| Normalized Diluted EPS | -80.23% | -977.64% | |||
| Average Basic Shares Outstanding | 0.41% | 1.47% | |||
| Average Diluted Shares Outstanding | 0.41% | 1.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||